Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech and Curis approved to begin skin cancer trial
Basal cell carcinoma is the most common form of all human cancers with approximately 800,000 to 1,000,000 new cases reported every year in the US. The drug candidate
Basal cell carcinoma is the most common form of all human cancers with approximately 800,000 to 1,000,000 new cases reported every year in the US. The drug candidate
The safety study’s objective was to compare the bioavailability of the current capsule formulation to two new formulations in pressed tablets. The results showed that the pressed tablets
According to Lorus, this most recent orphan drug status designation in acute myeloid leukemia (AML), together with an ongoing clinical study program using GTI-2040 in different drug combinations,
Sorafenib is a novel investigational drug candidate that has targeted members of two classes of kinases known to be involved in both tumor growth and tumor blood supply
In a 22-day study with an aggressively growing pancreatic tumor cell line, Noxxon researchers showed that tumor growth in a xenograft mouse model could be dramatically slowed by
A special protocol assessment (SPA) is a process in which the FDA provides evaluation and guidance on clinical trial protocols for phase III studies. The primary outcome measure
Preliminary results from a phase I study of the vascular endothelial growth factor (VEGF) Trap in 25 patients with advanced wet age-related macular degeneration (AMD) showed a statistically
New Jersey-based Memory Pharmaceuticals began a partnership with Roche in 2003. The project, known as the nicotinic alpha-7 collaboration, is focused on the development of nicotinic alpha-7 receptor
The study, details of which have been published in the Journal of Clinical Oncology, showed that 84% of patients who had no detectable traces of chronic lymphocytic leukemia
The agreement is said to be a six-figure deal, although the terms of the arrangement have not been released. Swiss Medica cited recent studies which have shown that